A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically documented colorectal cancer plus one of the following:
Failure of one prior irinotecan- or oxaliplatin-containing regimen, or
Adjuvant refractory to irinotecan- or oxaliplatin-containing regimen.
You may not be if
Prior treatment in first line metastatic setting with more than one regimen
Prior irradiation of more than 25% of bone marrow.
Clareo Health | A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen
